Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At PSA, Meet The New Deal-Makers (Part 1)

This article was originally published in The Pink Sheet Daily

Executive Summary

Two of the biopharma industry's newest heads of business development talked with Elsevier Business Intelligence Editor-in-Chief Chris Morrison at the Pharmaceutical Strategic Alliances conference on Sept. 22 in New York.

You may also be interested in...



AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program

Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.

AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program

Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.

At PSA, Meet The New Deal-Makers (Part 2)

At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel